Ratings Crescent Capital BDC, Inc.

Equities

CCAP

US2256551092

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
18.14 USD +0.50% Intraday chart for Crescent Capital BDC, Inc. +0.83% +4.37%

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Its low valuation, with P/E ratio at 7.43 and 8.54 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Closed End Funds

1st Jan change Capi. Investor Rating ESG Refinitiv
+4.37% 672M -
+7.69% 13.26B
C
+11.85% 9.55B -
C-
+2.65% 5.74B
D+
+7.30% 5.27B - -
-0.71% 5.11B -
D
+26.36% 4.99B - -
+20.18% 4.59B - -
+1.45% 3.98B -
+5.29% 3.97B -
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CCAP Stock
  4. Ratings Crescent Capital BDC, Inc.